Lucy Gilbert

QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 104 publications

Late metastatic recurrence of stage IA1 cervical cancer 12 years after minimally invasive radical hysterectomy.

Late metastatic recurrence of stage IA1 cervical cancer 12 years after minimally invasive radical hysterectomy.

Journal: Journal of minimally invasive gynecology
Published: August 05, 2026

Dexamethasone-associated hyperglycemia during chemotherapy in endometrial and ovarian cancer: a retrospective study.

Dexamethasone-associated hyperglycemia during chemotherapy in endometrial and ovarian cancer: a retrospective study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 15, 2026

Exploring the association between homologous recombination status, KELIM, and resectability in high-grade serous ovarian cancer.

Exploring the association between homologous recombination status, KELIM, and resectability in high-grade serous ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 06, 2026

The Impact of Pathogenic Variants of BRCA1, BRCA2 and Other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors - Single Center Experience from Quebec.

The Impact of Pathogenic Variants of BRCA1, BRCA2 and Other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors - Single Center Experience from Quebec.

Journal: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
Published: March 27, 2026

The Impact of Pathogenic Variants of BRCA1, BRCA2, and other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors-Single-Centre Experience from Quebec.

The Impact of Pathogenic Variants of BRCA1, BRCA2, and other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors-Single-Centre Experience from Quebec.

Journal: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
Published: March 27, 2026

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Journal: Gynecologic oncology
Published: March 24, 2026

From evidence to practice: national patterns of hyperthermic intra-peritoneal chemotherapy use and survival in advanced ovarian cancer.

From evidence to practice: national patterns of hyperthermic intra-peritoneal chemotherapy use and survival in advanced ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 15, 2026

Association of surgical approach with survival in clinically stage I uterine leiomyosarcoma: an National Cancer Database analysis.

Association of surgical approach with survival in clinically stage I uterine leiomyosarcoma: an National Cancer Database analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 28, 2026

Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.

Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 16, 2026

Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis.

Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 11, 2026

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)
Published: February 10, 2026

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 04, 2026
Showing 1-12 of 104

Last Updated: 09/26/2026